TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free NB100-56747 from Novus Biologicals, a Bio-Techne Brand

Product Specs
ItemTRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free
CompanyNovus Biologicals, a Bio-Techne Brand
Price $429.00Supplier Page View Company Product Page
Catalog NumberNB100-56747
ImmunogenThis monoclonal antibody was raised against a peptide corresponding to amino acid 2 to 21 of human DR4
Concentration1.0 mg/ml
Quantity0.1 mg (also 0.025 mg)
IsotypeIgG1 Kappa
ApplicationsFlow - CS,Flow Cytometry Control,Flow Cytometry,Western Blot,Flow (Cell Surface),Flow (Intracellular),Simple Western,CyTOF-ready,Immunocytochemistry/ Immunofluorescence
Clone32A1380
FormatPBS
Conjugate/TagUnconjugated
ClonalityMonoclonal
HostMouse
ReactivityHuman
TargetTRAILR1/TNFRSF10A
PurityProtein G purified
Research AreaApoptosis, Cancer
NCBI Full Gene NameTNF receptor superfamily member 10a
NCBI Gene AliasesTRAILR-1, TRAILR1, APO2, DR4, CD261
Antibody TypePrimary Antibodies
StorageStore at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Sizes Available: 0.1 mg (also 0.025 mg)

Add to Compare List

Novus Biologicals, a Bio-Techne Brand

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

Company Profile

Website: https://www.novusbio.com

(1) Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulationThe Journal of biological chemistryJanuary 1, 2021Chen L, Hao M, Yan J, Sun L, Tai G, Cheng H, Zhou Y.concentrations of DHCP for 24 h, collected, and washed with 2% FBS/PBS. The cells were labeled with anti-DR4 (NB100-56747, Novus Biologicals) or anti-DR5 (NB100-56618, Novus Biologicals) antibody for 20 min on ice and then

(2) Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathwaysMolecular medicine reportsJuly 1, 2017Xue M, Ge Y, Yu C, Zheng Z, He X, Zhao J.PATHWAY 979 receptor (DR) 4 and 5 were purchased from Imgenex; Novus Biologicals LLC (Littleton, CO, USA; NB100‑56747 and NB‑100‑55744). Antibodies against B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated X protein (Bax), Fas,

(3) NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5International journal of oncologyAugust 1, 2015Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF.

(4) Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapyScientific reportsDecember 20, 2013Qiu F, Hu M, Tang B, Liu X, Zhuang H, Yang J, Hua ZC.

(5) Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteinsMolecular and cellular biochemistryNovember 1, 2013Park S, Cho DH, Andera L, Suh N, Kim I.

(6) Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axisPloS oneJanuary 1, 2013Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS.

(7) Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesMolecular cancer therapeuticsOctober 1, 2012Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS.

(8) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathwayMolecular cancer therapeuticsJanuary 1, 2011Jane EP, Premkumar DR, Pollack IF.

(9) CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cellsCancer researchJuly 1, 2008Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY.

(10) Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cellsCancer immunology, immunotherapy : CIIJune 1, 2008Le Poole IC, ElMasri WM, Denman CJ, Kroll TM, Bommiasamy H, Lyons Eiben G, Kast WM.

(11) Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumorsCancer gene therapyAugust 1, 2007Tsurushima H, Yuan X, Dillehay LE, Leong KW.

(12) E2 of hepatitis C virus inhibits apoptosisJournal of immunology (Baltimore, Md. : 1950)December 15, 2005Lee SH, Kim YK, Kim CS, Seol SK, Kim J, Cho S, Song YL, Bartenschlager R, Jang SK.

(13) 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligoThe Journal of investigative dermatologyApril 1, 2005Kroll TM, Bommiasamy H, Boissy RE, Hernandez C, Nickoloff BJ, Mestril R, Caroline Le Poole I.

(14) Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particleMolecular biology of the cellNovember 1, 2004Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL.

(15) p53 upregulates death receptor 4 expression through an intronic p53 binding siteCancer researchAugust 1, 2004Liu X, Yue P, Khuri FR, Sun SY.

(16) Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivationOncogeneMarch 20, 2003Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, et al.

(17) Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signalingCancer researchMarch 1, 2003Chen X, Kandasamy K, Srivastava RK.

(18) Evidence that the human death receptor 4 is regulated by activator protein 1OncogeneMay 9, 2002Guan B, Yue P, Lotan R, Sun SY.

(19) Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cellsCell death and differentiationMarch 1, 2002Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr.

(20) Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligandJournal of immunology (Baltimore, Md. : 1950)February 15, 2002Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL.

Be the First to Write a Review!

TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free

TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free

TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free

TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free from Novus Biologicals, a Bio-Techne Brand

Specifications/Features

Novus Biologicals, a Bio-Techne Brand

Citations (22)

Reviews

TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free from Novus Biologicals, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map